Zogenix Inc (ZGNX) 1.43 $ZGNX
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
GlobeNewswire - Tue Feb 10, 3:08PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum, Pharm.D., has been appointed as a new member of the Company's Board of Directors.
ZGNX: 1.43 (+0.05)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
Zogenix Approval Sheds Light On Path For Elite Pharmaceuticals
Matt's Stocks - Seeking Alpha - Fri Feb 06, 7:00AM CST
The recent approval of a reformulated version of Zohydro has shed some light on the path that Elite Pharmaceuticals ( OTCQB:ELTP ) may be taking to garner approval. Elite Pharma noted to investors in November that some additional but small...
ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23)
Zogenix to Participate in Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 10:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that Ann Rhoads, Chief Financial Officer, will present at the Leerink Global Healthcare Conference in New York, NY on February 11, 2015. Ms. Rhoads will participate in a fireside chat presentation and provide a general company update.
ZGNX: 1.43 (+0.05)
Zogenix (ZGNX) Stock Rises Today on Zohydro FDA Approval
at The Street - Mon Feb 02, 3:12PM CST
Zogenix (ZGNX) shares are climbing after the company announced that the FDA approved the new version of its pain killer Zohydro.
ZGNX: 1.43 (+0.05)
Zogenix volume up after approval but little headway
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 12:22PM CST
ZGNX: 1.43 (+0.05)
Zogenix gets approval for new version of painkiller
By MATTHEW PERRONE - AP - Mon Feb 02, 10:48AM CST
WASHINGTON (AP) — Zogenix Inc. has received U.S. approval for a new formulation of its much-debated painkiller Zohydro that is intended to be harder to abuse, though the company is still working on studies needed to promote that claim.
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 8:12AM CST
BGMD: 0.88 (unch), SD: 2.09 (+0.14), FRO: 2.96 (+0.07), CAMT: 3.08 (+0.09), PWE: 2.45 (+0.02), HIHO: 3.30 (-0.17), PSTI: 2.91 (+0.01), ZGNX: 1.43 (+0.05), NBG: 1.61 (+0.18), SDRL: 12.32 (-0.70), GURE: 1.64 (-0.04)
Pharma Equities Under the Scanner - Pfizer, Sanofi, Eli Lilly, AstraZeneca, and Zogenix
PR Newswire - Mon Feb 02, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Sanofi (NYSE: SNY), Eli Lilly and Company (NYSE: LLY), AstraZeneca PLC (NYSE: AZN), and Zogenix Inc. (NASDAQ: ZGNX). Free research report on Pfizer can be accessed at http://get.Investor-Edge.com/pdf/?c=Pfizer&am...&s=PFE. The US markets on Friday, January 30, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,164.95, down 1.45% and the NASDAQ Composite closed at 4,635.24, down 1.03%. The S&P 500 finished the session 1.30% lower at 1,994.99. During the trading session, nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 801.26, down 1.53%, whereas the index has advanced 2.88% in the previous three months. Register for your complimentary reports at the links given below.
ZGNX: 1.43 (+0.05), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82)
FDA clears abuse-deterrent formulation of Zohydro
Seeking Alpha - at Seeking Alpha - Sat Jan 31, 11:35AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
GlobeNewswire - Fri Jan 30, 6:05PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek(TM). BeadTek is a formulation technology designed to provide abuse-deterrent properties without changing the release properties of hydrocodone when Zohydro ER is used as intended. Concurrently, Zogenix has ongoing Human Abuse Liability studies, which will further characterize the abuse-deterrent properties of the new formulation. Zogenix intends to submit these data in the second half of 2015 to the FDA to support an amended product label, including abuse-deterrent claims consistent with the FDA's current draft Guidance for Industry, Abuse-Deterrent Opioids - Evaluation and Labeling.
ZGNX: 1.43 (+0.05)
PDUFA date approaches for Zohydro sNDA
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 12:18PM CST
ZGNX: 1.43 (+0.05)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Zogenix: A Strong Turnaround For 2015
Ian Niemeyer - at Seeking Alpha - Thu Jan 22, 3:07PM CST
ZGNX: 1.43 (+0.05)
Zogenix Provides Business Update
GlobeNewswire - Mon Jan 12, 6:44AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights, the most recent Zohydro ER prescription trends and the Company's year-end 2014 cash position.
ZGNX: 1.43 (+0.05)
Zogenix 2015 Expectations and Developments Drive Price Upward: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Jan 05, 6:00AM CST
Zogenix Inc. (NASDAQ: ZGNX) is a California-based pharmaceutical company that develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company's two main products include Zohydro (a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain) and Relday (an injectable formulation of risperidone formulated to treat the symptoms of schizophrenia and bipolar disorder, and which is in a Phase I clinical trial). Zogenix was founded in 2006 with its headquarter located in San Diego, California.
ZGNX: 1.43 (+0.05)
Zogenix (ZGNX) Looks Good: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:25AM CST
Zogenix (ZGNX) was a big mover last session, with shares rising nearly 9% on the day.
ZGNX: 1.43 (+0.05), CEMP: 27.68 (+1.25)
Zogenix sets up expensive $24M credit facility
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:13AM CST
ZGNX: 1.43 (+0.05)
Money flows into Zogenix today
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 2:49PM CST
ZGNX: 1.43 (+0.05)
FDA accepts Pfizer's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:22AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Zogenix Appoints Industry Veteran Renee Tannenbaum to Its Board of Directors
GlobeNewswire - Tue Feb 10, 3:08PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that Renee Tannenbaum, Pharm.D., has been appointed as a new member of the Company's Board of Directors.
ZGNX: 1.43 (+0.05)
Buying This Biotech Is Like Purchasing a Lottery Ticket
Motley Fool Staff - Motley Fool - Sun Feb 08, 11:59AM CST
Source: Flickr user Mark Ou . The lottery may be a fun distraction, but it's no way to plan for your future financial security. Despite that fact, everyday investors make big bets on high-risk stocks that are at best big-time gambles and at worst...
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), AEGR: 25.15 (+0.88), EXEL: 2.48 (+0.20)
Zogenix Approval Sheds Light On Path For Elite Pharmaceuticals
Matt's Stocks - Seeking Alpha - Fri Feb 06, 7:00AM CST
The recent approval of a reformulated version of Zohydro has shed some light on the path that Elite Pharmaceuticals ( OTCQB:ELTP ) may be taking to garner approval. Elite Pharma noted to investors in November that some additional but small...
ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23)
Zogenix to Participate in Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 10:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that Ann Rhoads, Chief Financial Officer, will present at the Leerink Global Healthcare Conference in New York, NY on February 11, 2015. Ms. Rhoads will participate in a fireside chat presentation and provide a general company update.
ZGNX: 1.43 (+0.05)
Zogenix (ZGNX) Stock Rises Today on Zohydro FDA Approval
at The Street - Mon Feb 02, 3:12PM CST
Zogenix (ZGNX) shares are climbing after the company announced that the FDA approved the new version of its pain killer Zohydro.
ZGNX: 1.43 (+0.05)
Zogenix volume up after approval but little headway
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 12:22PM CST
ZGNX: 1.43 (+0.05)
Zogenix gets approval for new version of painkiller
By MATTHEW PERRONE - AP - Mon Feb 02, 10:48AM CST
WASHINGTON (AP) — Zogenix Inc. has received U.S. approval for a new formulation of its much-debated painkiller Zohydro that is intended to be harder to abuse, though the company is still working on studies needed to promote that claim.
ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 8:12AM CST
BGMD: 0.88 (unch), SD: 2.09 (+0.14), FRO: 2.96 (+0.07), CAMT: 3.08 (+0.09), PWE: 2.45 (+0.02), HIHO: 3.30 (-0.17), PSTI: 2.91 (+0.01), ZGNX: 1.43 (+0.05), NBG: 1.61 (+0.18), SDRL: 12.32 (-0.70), GURE: 1.64 (-0.04)
Pharma Equities Under the Scanner - Pfizer, Sanofi, Eli Lilly, AstraZeneca, and Zogenix
PR Newswire - Mon Feb 02, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Sanofi (NYSE: SNY), Eli Lilly and Company (NYSE: LLY), AstraZeneca PLC (NYSE: AZN), and Zogenix Inc. (NASDAQ: ZGNX). Free research report on Pfizer can be accessed at http://get.Investor-Edge.com/pdf/?c=Pfizer&am...&s=PFE. The US markets on Friday, January 30, 2015, ended on a negative note as the Dow Jones Industrial Average finished at 17,164.95, down 1.45% and the NASDAQ Composite closed at 4,635.24, down 1.03%. The S&P 500 finished the session 1.30% lower at 1,994.99. During the trading session, nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 801.26, down 1.53%, whereas the index has advanced 2.88% in the previous three months. Register for your complimentary reports at the links given below.
ZGNX: 1.43 (+0.05), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), LLY: 70.56 (+0.03), SNY: 49.42 (+0.82)
FDA clears abuse-deterrent formulation of Zohydro
Seeking Alpha - at Seeking Alpha - Sat Jan 31, 11:35AM CST
MNK: 115.01 (+2.51), LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), ALKS: 71.40 (-1.89)
Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER
GlobeNewswire - Fri Jan 30, 6:05PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek(TM). BeadTek is a formulation technology designed to provide abuse-deterrent properties without changing the release properties of hydrocodone when Zohydro ER is used as intended. Concurrently, Zogenix has ongoing Human Abuse Liability studies, which will further characterize the abuse-deterrent properties of the new formulation. Zogenix intends to submit these data in the second half of 2015 to the FDA to support an amended product label, including abuse-deterrent claims consistent with the FDA's current draft Guidance for Industry, Abuse-Deterrent Opioids - Evaluation and Labeling.
ZGNX: 1.43 (+0.05)
PDUFA date approaches for Zohydro sNDA
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 12:18PM CST
ZGNX: 1.43 (+0.05)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Zogenix: A Strong Turnaround For 2015
Ian Niemeyer - at Seeking Alpha - Thu Jan 22, 3:07PM CST
ZGNX: 1.43 (+0.05)
Zogenix Provides Business Update
GlobeNewswire - Mon Jan 12, 6:44AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system (CNS) disorders, announced today a business update including recent company highlights, the most recent Zohydro ER prescription trends and the Company's year-end 2014 cash position.
ZGNX: 1.43 (+0.05)
Zogenix 2015 Expectations and Developments Drive Price Upward: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Jan 05, 6:00AM CST
Zogenix Inc. (NASDAQ: ZGNX) is a California-based pharmaceutical company that develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company's two main products include Zohydro (a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain) and Relday (an injectable formulation of risperidone formulated to treat the symptoms of schizophrenia and bipolar disorder, and which is in a Phase I clinical trial). Zogenix was founded in 2006 with its headquarter located in San Diego, California.
ZGNX: 1.43 (+0.05)
Zogenix (ZGNX) Looks Good: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:25AM CST
Zogenix (ZGNX) was a big mover last session, with shares rising nearly 9% on the day.
ZGNX: 1.43 (+0.05), CEMP: 27.68 (+1.25)
Zogenix sets up expensive $24M credit facility
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:13AM CST
ZGNX: 1.43 (+0.05)
Money flows into Zogenix today
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 2:49PM CST
ZGNX: 1.43 (+0.05)
